This review highlights current and potential future pharmacological agents for rhythm control in atrial fibrillation, emphasizing the need to overcome limitations of current therapies such as marginal efficacy and proarrhythmia.
Current AF rhythm-control drugs have limited efficacy and safety; leaves open development of improved agents.
Atrial fibrillation is the most commonly encountered cardiac arrhythmia and is directly or indirectly responsible for considerable mortality, morbidity and health care burden. The available medical therapy is limited by marginal efficacy, end-organ toxicity, as well as the potential for undesired ventricular proarrhythmia. Elucidation of the potential mechanisms that underlie the development of atrial fibrillation may provide new targets for drugs that circumvent the problems associated with current medical options. This review focuses on the current and potential future pharmacological agents directed at rhythm control and maintenance of sinus rhythm.
No takes yet. Share an insight, caveat, or question.
Viswanathan et al. (2009) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: